FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898834138> ?p ?o ?g. }

• W2898834138 endingPage "2097" @default.
• W2898834138 startingPage "2087" @default.
• W2898834138 abstract "Duchenne Muscular Dystrophy (DMD) is the most prevalent dystrophy of childhood and is characterized by generalized motor delays due to progressive muscular weakness, leading to loss of muscle mass. Additionally, patients with DMD develop obesity, hyperinsulinemia, and Insulin Resistance (IR). Omega-3 Long-Chain PolyUnsaturated Fatty Acids (Ω-3LCPUFA) increase fat mass, decrease lean mass, and decrease hyperinsulinemia and IR. The aim of this study was to analyze the impact of Ω-3LCPUFA consumption on lean mass, fat mass, hyperinsulinemia, and IR in children with DMD.This placebo-controlled, double-blind, randomized study was carried out in 28 patients with DMD supplemented with 2.9 g/d of Ω-3LCPUFA (n = 14) or sunflower oil (placebo, n = 14) during 6 months. Serum glucose and insulin were measured at baseline and thereafter at months 3 and 6 of the intervention to estimate IR by HOmeostasis Model Assessment. Body composition was assessed by Dual Energy X-ray Absorptiometry.The percentage of change in EicosaPentaenoic Acid (EPA) and DocosaHexaenoic Acid (DHA) in erythrocytes was significantly (p < 0.05) higher in boys who consumed Ω-3LCPUFA than in the placebo group. Lean mass and fat mass (both in g/kg of Body Weight [BW]) had a trend toward being higher (p = 0.07 at month 3 and p = 0.085 at month 6) and lower (p = 0.05 at month 3 and p = 0.085 at month 6) respectively, in boys with DMD supplemented with Ω-3LCPUFA compared with the placebo group. The loss of lean mass was delayed in the Ω-3LCPUFA group; it started at month 6 but, in placebo, it started at month 3 of supplementation in comparison with the baseline of each group. Fasting insulin, percentage of boys with hyperinsulinemia, and IR were similar between the placebo and Ω-3LCPUFA groups during the 6 months of supplementation. The percentage of boys with IR was significantly (p = 0.045) lower at month 6 of supplementation in the Ω-3LCPUFA group than in the placebo group.This study suggests that Ω-3LCPUFA (2.9 g/day) intake during 6 months likely slows the progression of muscle loss, decreases the fat mass, and reduces IR in boys with DMD. The findings of this study provide scientific background for conducting a randomized trial focused of confirming the possible beneficial role of Ω-3LCPUFA on the previously mentioned alterations mentioned in boys with early muscle damage (without fibrosis) DMD. This research was registered at clinicaltrials.gov (NCT018264229)." @default.
• W2898834138 created "2018-11-09" @default.
• W2898834138 creator A5003090928 @default.
• W2898834138 creator A5013177334 @default.
• W2898834138 creator A5014643341 @default.
• W2898834138 creator A5014808769 @default.
• W2898834138 creator A5027365329 @default.
• W2898834138 creator A5037416049 @default.
• W2898834138 creator A5075871687 @default.
• W2898834138 creator A5083668292 @default.
• W2898834138 date "2019-10-01" @default.
• W2898834138 modified "2023-10-18" @default.
• W2898834138 title "Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study" @default.
• W2898834138 cites W1855151202 @default.
• W2898834138 cites W1941910566 @default.
• W2898834138 cites W1967696666 @default.
• W2898834138 cites W1974926812 @default.
• W2898834138 cites W1982385357 @default.
• W2898834138 cites W2024417353 @default.
• W2898834138 cites W2027221381 @default.
• W2898834138 cites W2033671850 @default.
• W2898834138 cites W2034557838 @default.
• W2898834138 cites W2041695177 @default.
• W2898834138 cites W2048032483 @default.
• W2898834138 cites W2074620127 @default.
• W2898834138 cites W2095252907 @default.
• W2898834138 cites W2105137212 @default.
• W2898834138 cites W2113332979 @default.
• W2898834138 cites W2113599741 @default.
• W2898834138 cites W2114134430 @default.
• W2898834138 cites W2117572940 @default.
• W2898834138 cites W2126611911 @default.
• W2898834138 cites W2128410890 @default.
• W2898834138 cites W2130246145 @default.
• W2898834138 cites W2130884450 @default.
• W2898834138 cites W2134293572 @default.
• W2898834138 cites W2141885792 @default.
• W2898834138 cites W2142420569 @default.
• W2898834138 cites W2142932338 @default.
• W2898834138 cites W2143608684 @default.
• W2898834138 cites W2152817152 @default.
• W2898834138 cites W2154345621 @default.
• W2898834138 cites W2159743653 @default.
• W2898834138 cites W2160234571 @default.
• W2898834138 cites W2610366065 @default.
• W2898834138 cites W2745950617 @default.
• W2898834138 cites W2758378616 @default.
• W2898834138 cites W2784992484 @default.
• W2898834138 cites W4245769669 @default.
• W2898834138 doi "https://doi.org/10.1016/j.clnu.2018.10.017" @default.
• W2898834138 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30420291" @default.
• W2898834138 hasPublicationYear "2019" @default.
• W2898834138 type Work @default.
• W2898834138 sameAs 2898834138 @default.
• W2898834138 citedByCount "12" @default.
• W2898834138 countsByYear W28988341382020 @default.
• W2898834138 countsByYear W28988341382021 @default.
• W2898834138 countsByYear W28988341382022 @default.
• W2898834138 countsByYear W28988341382023 @default.
• W2898834138 crossrefType "journal-article" @default.
• W2898834138 hasAuthorship W2898834138A5003090928 @default.
• W2898834138 hasAuthorship W2898834138A5013177334 @default.
• W2898834138 hasAuthorship W2898834138A5014643341 @default.
• W2898834138 hasAuthorship W2898834138A5014808769 @default.
• W2898834138 hasAuthorship W2898834138A5027365329 @default.
• W2898834138 hasAuthorship W2898834138A5037416049 @default.
• W2898834138 hasAuthorship W2898834138A5075871687 @default.
• W2898834138 hasAuthorship W2898834138A5083668292 @default.
• W2898834138 hasConcept C120863210 @default.
• W2898834138 hasConcept C126322002 @default.
• W2898834138 hasConcept C134018914 @default.
• W2898834138 hasConcept C142724271 @default.
• W2898834138 hasConcept C147583825 @default.
• W2898834138 hasConcept C185592680 @default.
• W2898834138 hasConcept C19038510 @default.
• W2898834138 hasConcept C204787440 @default.
• W2898834138 hasConcept C27081682 @default.
• W2898834138 hasConcept C2776091944 @default.
• W2898834138 hasConcept C2777171753 @default.
• W2898834138 hasConcept C2777391703 @default.
• W2898834138 hasConcept C2778943923 @default.
• W2898834138 hasConcept C2779306644 @default.
• W2898834138 hasConcept C2780988686 @default.
• W2898834138 hasConcept C543025807 @default.
• W2898834138 hasConcept C55493867 @default.
• W2898834138 hasConcept C71924100 @default.
• W2898834138 hasConceptScore W2898834138C120863210 @default.
• W2898834138 hasConceptScore W2898834138C126322002 @default.
• W2898834138 hasConceptScore W2898834138C134018914 @default.
• W2898834138 hasConceptScore W2898834138C142724271 @default.
• W2898834138 hasConceptScore W2898834138C147583825 @default.
• W2898834138 hasConceptScore W2898834138C185592680 @default.
• W2898834138 hasConceptScore W2898834138C19038510 @default.
• W2898834138 hasConceptScore W2898834138C204787440 @default.
• W2898834138 hasConceptScore W2898834138C27081682 @default.
• W2898834138 hasConceptScore W2898834138C2776091944 @default.
• W2898834138 hasConceptScore W2898834138C2777171753 @default.
• W2898834138 hasConceptScore W2898834138C2777391703 @default.

• next